Mori K, Hibasami H, Sonoda J, Fujinami S, Sekiguchi S, Tajima M, Yamazaki T, Higuchi S, Uchida A, Nakashima K
Department of Orthopedic Surgery, College of Medical Sciences, Mie University, Japan.
Anticancer Res. 1996 Sep-Oct;16(5A):2565-7.
Our previous experiments have indicated that the antitumor effects of a polyamine biosynthetic inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP), on human osteosarcoma cell lines such as MG-63, G-292 and HOS cells are obtained by its action depleting the cellular polyamine contents. In the present study, the effects of polyamine depletion by MGBCP on the cell cycle progression in these osteosarcoma cell lines were investigated by flow cytofluormetric analysis. MGBCP arrested the tumor cells at the G1 phase by preventing the G/S phase transition. Mitotic indexes (MIs) in these MGBCP-inhibited tumor cells were also decreased. These findings suggest that MGBCP suppresses the cell cycle progression in osteosarcoma MG-63, G-292 and HOS cells by inhibiting intracellular polyamine biosynthesis.
我们之前的实验表明,多胺生物合成抑制剂甲基乙二醛双(环戊基脒腙)(MGBCP)对人骨肉瘤细胞系如MG-63、G-292和HOS细胞的抗肿瘤作用是通过其耗尽细胞内多胺含量的作用实现的。在本研究中,通过流式细胞荧光分析研究了MGBCP引起的多胺耗竭对这些骨肉瘤细胞系细胞周期进程的影响。MGBCP通过阻止G/S期转换使肿瘤细胞停滞在G1期。这些MGBCP抑制的肿瘤细胞中的有丝分裂指数(MIs)也降低了。这些发现表明,MGBCP通过抑制细胞内多胺生物合成来抑制骨肉瘤MG-63、G-292和HOS细胞的细胞周期进程。